Cervical cancer is the second most common type of cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically proven to be the primary cause of cervical cancer. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens.
What the Market Looks Like?
The global HPV testing and Pap test market is projected to reach USD 4.52 billion by 2020 from USD 3.29 billion in 2015, at a CAGR of 6.6% from 2015 to 2020. The HPV testing and Pap test market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).
However, these tests are unable to detect all the genotypes causing HPV infections and might also lead to a significant number of false negative results. Owing to these challenges posed by Pap tests, HPV diagnostic tests were introduced as effective molecular diagnostic tests.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371
What Drives the Market?
The growth of the HPV Testing and Pap Test Market is primarily influenced by the following factors:
- Increasing number of cervical cancer cases and growing aging population
- Increasing awareness of cervical cancer screening programs
- Government initiatives and funding.
On the basis of end user, the HPV testing and Pap test market is categorized into hospitals, laboratories, physician’s offices and clinics. The hospitals segment is projected to grow at the highest CAGR from 2015 to 2020. This growth is attributed to the increasing patient volumes in hospitals, as most diagnostic tests are carried out in-house with advanced technologies and more accessibility.
Read more about HPV Testing and Pap Test Market @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371
Comments
Post a Comment